Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863430 | 0.92 | GPR119 (0.46) | GPR119KDM4EPKMFAAH | |
| SCHEMBL7863491 | 0.91 | GPR119 (0.45) | GPR119KDM4EPKMFAAH | |
| SCHEMBL7870206 | 0.83 | PIM1 (0.38) | — | |
| SCHEMBL7870260 | 0.82 | PIM1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL7863541 | 0.81 | PIM1 (0.36) | — | |
| SCHEMBL8713112 | 0.79 | GPR119 (0.45) | GPR119KDM4EPKMFAAH | |
| SCHEMBL7863410 | 0.78 | PIK3CA (0.46) | FPR2GPR119KDM4EPKMBACE1 | |
| SCHEMBL7868718 | 0.77 | PIK3CA (0.46) | GPR119KDM4EPKMBACE1FAAH | |
| SCHEMBL6152303 | 0.74 | HTR1A (0.53) | FPR2GPR119KDM4EPKMTP53 | |
| SCHEMBL7871693 | 0.74 | GPR119 (0.43) | GPR119KDM4EPKMFAAHPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10236952-A | — | — | None | — | — | JP | disclosed |
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| US-5958942-A | HAVING EXCELLENT PDGF-INHIBITING ACTIVITIES, ANTIHYPERTENSIVE ACTIVITIES, ACTIVITIES OF AMELIORATING RENAL DISEASES AND ACTIVITIES OF LOWERING LIPID LEVEL. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-28 | — | — | US | disclosed |
| JP-H10236952-A | STABLE PHARMACEUTICAL COMPOSITION | TAKEDA CHEM IND LTD | 1998-09-08 | — | — | JP | disclosed |
| EP-0826686-A2 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | FPR2 2690/4885GPR119 605/4885KDM4E 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.